Form 4: Kura Oncology Director Faheem Hasnain Receives Stock Option

Director Faheem Hasnain was granted an option to purchase 35,000 shares of Kura Oncology common stock.

Summary

• Director Faheem Hasnain received a grant of 35,000 stock options on June 4, 2026.
• The options have an exercise price of $8.77 per share.
• The options are set to expire on June 3, 2036.
• The grant vests in full on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• Potential for future dilution of equity.

Future Outlook

The options vest in full on June 4, 2027, aligning the director's interest with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term commitment and alignment with corporate milestones.

Comparison to Industry Standards

• The grant of 35,000 options is consistent with typical director compensation packages for mid-cap oncology firms.
• Vesting schedules of one year are common for non-employee director equity awards in the life sciences industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Trading, Stock Options, Director Compensation